Log in to save to my catalogue

Safety and efficacy of intrathecal antibodies to Nogo-A in patients with acute cervical spinal cord...

Safety and efficacy of intrathecal antibodies to Nogo-A in patients with acute cervical spinal cord...

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_miscellaneous_3147973186

Safety and efficacy of intrathecal antibodies to Nogo-A in patients with acute cervical spinal cord injury: a randomised, double-blind, multicentre, placebo-controlled, phase 2b trial

Publication information

Publisher

England: Elsevier Ltd

More information

Scope and Contents

Contents

Spinal cord injury results in permanent neurological impairment and disability due to the absence of spontaneous regeneration. NG101, a recombinant human antibody, neutralises the neurite growth-inhibiting protein Nogo-A, promoting neural repair and motor recovery in animal models of spinal cord injury. We aimed to evaluate the efficacy of intrathe...

Alternative Titles

Full title

Safety and efficacy of intrathecal antibodies to Nogo-A in patients with acute cervical spinal cord injury: a randomised, double-blind, multicentre, placebo-controlled, phase 2b trial

Identifiers

Primary Identifiers

Record Identifier

TN_cdi_proquest_miscellaneous_3147973186

Permalink

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_miscellaneous_3147973186

Other Identifiers

ISSN

1474-4422,1474-4465

E-ISSN

1474-4465

DOI

10.1016/S1474-4422(24)00447-2

How to access this item